Top View
- Application of Nanoparticles for the Development of New Antituberculosis Therapies Joana Costa Gouveia
- 2019 Antibacterial Agents in Clinical Development
- Sputum Biomarkers and Regulatory Innovation for MDR-TB Regimens
- Dr-Tb Drugs Under the Microscope Issue Issue Brief 6Th Edition
- In Vitro E Cacy Comparison of Linezolid, Tedizolid, Sutezolid And
- Antibiotics in the Clinical Pipeline in October 2019
- Immunology Product Handbook
- An Activist's Guide to Tuberculosis Drugs 2016 Update
- Sutezolid for the Treatment of Tuberculosis Clinical Development Status: Phase 2
- Antibiotics in Late Clinical Development
- Besifloxacin for the Treatment of Resistant Acne Besifloxacin Zur Behandlung Von Resistenter Akne Besifloxacin Pour Traiter L’Acné Résistante
- A A21978C, 110 A54145, 110 Acinetobacter Baumannii, 29, 31, 38 Actinobacteria, 7 Actinonin, 279, 288 Agar-Diffusion Technologies
- Biotechs Are Saving the World from Superbugs. Can They Also Save Themselves?
- The Enlarging Threat of Antibiotic Resistance
- ANTIBACTERIAL AGENTS in CLINICAL DEVELOPMENT an Analysis of the Antibacterial Clinical Development Pipeline, Including Tuberculosis
- Developing Methods to Prioritize in Vitro Drug Combinations Against Mycobacterium Tuberculosis
- Antibiotics in the Clinical Pipeline in 2013
- New Drugs for the Treatment of Tuberculosis
- Medicines in Development ꟷ Infectious Diseases